OC.02.6 BASELINE IL-23 SERUM LEVELS PREDICT MUCOSAL HEALING IN PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB. A PROSPECTIVE STUDY.

MLA

Bertani, L., et al. “Oc.02.6 Baseline Il-23 Serum Levels Predict Mucosal Healing in Patients with Crohn’s Disease Treated with Ustekinumab. A Prospective Study.” Digestive & Liver Disease, vol. 54, May 2022, p. S73. EBSCOhost, https://doi.org/10.1016/S1590-8658(22)00283-3.

APA

Bertani, L., D’Antongiovanni, V., Coppini, F., Benvenuti, L., Bronzini, F., Ceccarelli, L., Fornai, M., De Bortoli, N., Bellini, M., Antonioli, L., & Costa, F. (2022). Oc.02.6 Baseline Il-23 Serum Levels Predict Mucosal Healing in Patients with Crohn’s Disease Treated with Ustekinumab. A Prospective Study. Digestive & Liver Disease, 54, S73. https://doi.org/10.1016/S1590-8658(22)00283-3

Chicago

Bertani, L., V. D’Antongiovanni, F. Coppini, L. Benvenuti, F. Bronzini, L. Ceccarelli, M. Fornai, et al. 2022. “Oc.02.6 Baseline Il-23 Serum Levels Predict Mucosal Healing in Patients with Crohn’s Disease Treated with Ustekinumab. A Prospective Study.” Digestive & Liver Disease 54 (May): S73. doi:10.1016/S1590-8658(22)00283-3.